Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination

Science China Life Sciences

Volumn 54, Issue 3, 2011, Pages 263-266

  Wang, Zhan ^a   Yang, Song Mei ^a   Zhou, Ling ^a   Du, Hai Jun ^a   Mo, Wu Ning ^b   Zeng, Yi ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

combinatorial immunization; DNA vaccine; EBV LMP2; recombinant adeno associated virus vaccine; recombinant adenovirus vaccine; specific cell mediated immune responses

Indexed keywords

DNA; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; VIRUS VACCINE;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; NASOPHARYNX CARCINOMA; NASOPHARYNX TUMOR;

ADENOVIRIDAE; ANIMALS; DEPENDOVIRUS; DNA; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; NASOPHARYNGEAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS; VIRAL VACCINES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; HUMAN HERPESVIRUS 4; MUS;

EID: 79952834825     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-011-4147-0     Document Type: Article

References (19)

1. Chan A T, Toe P M, Johnson P J. Nasopharyngeal carcinoma. Ann Oncol, 2002, 13: 1007-1025.
2. Yu M C. Nasopharyngeal carcinoma: Epidemiology and dietary factors. IARC Sci Publ, 1991, 105: 39-47.
3. Taylor G S. T cell-based therapies for EBV-associated malignancies. Expert Opin Biol Ther, 2004, 4: 11-21.
4. Lennette E T, Winberg G, Yadav M, et al. Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur J Cancer, 1995, 31A: 1875-1878.
5. Lee S P, Tierney R J, Thomas W A, et al. Conserved CTL epitopes within EBV latent membrane protein 2: A potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325-3334.
6. Lee S P, Chan A T, Cheung S T, et al. CTL control of EBV in nasopharyngeal carcinoma: EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol, 2000, 165: 573-582.
7. Konishi K, Maruo S, Kato H, et al. Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol, 2001, 82: 1451-1456.
8. Straathof K C, Leen A M, Buza E L, et al. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol, 2005, 175: 4137-4147.
9. Rooney C M, Smith C A, Ng C Y, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus related lympholiferation. Lancet, 1995, 345: 9-13.
10. Zuo J M, Zhou L, Wang Q, et al. The in vitro and in vivo immunogenicity of recombination adenovirus vaccine containing EBV-latent membrane protein 2. Chin J Microbiol Immunol, 2003, 23: 446-449.
11. Ghosh S S, Gopinath P, Ramesh A. Adenoviral vectors: A promising tool for gene therapy. Appl Biotechnol, 2006, 133: 9-29.
12. Excler J L, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS, 1997, 11: S127-137.
13. Donnelly J J, Ulmer J B, Shiver J W. DNA vaccines. Annu Rev Immunol, 1997, 15: 617-648.
14. Li C, Bowles D E, Dyke T V. Adeno-associated virus vectors: Potential applications for cancer gene therapy. Cancer Gene Ther, 2005, 12: 913-925.
15. Excler J L. AIDS vaccine development: Perspectives, challenges & hopes. Indian J Med Res, 2005, 121: 568-581.
16. Casimiro D R, Chen L, Fu T M. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol, 2003, 77: 6305-6313.
17. Xin K Q, Jounai N, Someya K. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther, 2005, 12: 1769-1777.
18. Ponnazhagan S. Adenoassociated virus vectors for genetic immunization. Immunol Res, 2002, 26: 247-253.
19. Nikitina E Y, Chada S, Muro-Cacho C. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther, 2002, 9: 345-352.